CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects
Executive Summary
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
You may also be interested in...
US FDA On Effects From Cannabinoids Potentially Differing By Gender: Stay Tuned
"The use of these products during pregnancy and lactation raises additional questions and concerns,” says Kaveeta Vasisht, FDA Office of Women’s Health director. "There is a great deal that we simply do not yet know about CBD and beyond CBD, even more that we do not know about the other compounds found in hemp," said Douglas Throckmorton, Center for Drug Evaluation and Research deputy director.
Lawful Use Of Cannabidiols In Supplements ‘Different Than The Rest’ Of US FDA Regulations?
CFSAN regulatory affairs chief Douglas Stearn says a regulatory pathway wouldn’t be an open door for CBD-containing food and supplements due to concerns about the ingredients’ safety. Legislation from Congress might "do something with CBD that’s different than the rest of the Food, Drug and Cosmetic Act," he says.
CBD Drug Approval Not A Sign FDA Will Allow Its Use In Supplements
As a Schedule I controlled substance, CBD is not allowed by FDA for use in dietary supplements. Although CBD will be rescheduled by DEA to a less prohibitive Controlled Substances Act classification before GW Pharmaceuticals can launch its drug FDA approved June 25, its status for use in supplements won't change.